Fax: (310) 998-3965
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma†
A randomized, double-blind, multicenter, comparative trial
Article first published online: 29 AUG 2003
Copyright © 2003 American Cancer Society
Volume 98, Issue 8, pages 1735–1744, 15 October 2003
How to Cite
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., Chen, B.-L. and Seaman, J. J. (2003), Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer, 98: 1735–1744. doi: 10.1002/cncr.11701
Performed on behalf of the Zoledronic Acid Breast Cancer and Multiple Myeloma Study Group
- Issue published online: 3 OCT 2003
- Article first published online: 29 AUG 2003
- Manuscript Accepted: 14 JUL 2003
- Manuscript Revised: 23 JUN 2003
- Manuscript Received: 5 MAR 2003
- Novartis Pharmaceuticals Corporation (East Hanover, New Jersey)
- 10RiesLAG, EisnerMP, KosaryCL, et al., editors. SEER cancer statistics review, 1973–1999. Bethesda: National Cancer Institute, 2001.
- 12Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88: 1082–1090., , , et al.
- 18Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin J Oncol Nurse. 2003; 7: 403–410., , , , .
- 20Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial. The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21: 3150–3157., , , et al.
- 22Zoledronic acid (Zol) significantly reduces skeletal-related events (SREs) in patients with bone metastases from solid tumors [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 295a., , , et al.